An open letter to the CPAs who audit R&D charities receiving GIK meds
(Cross-post from my other blog, Nonprofit Update.)
Dear colleagues:
If you would like some background on the GIK issues, please read my open letter to your clients.
The accounting is problematic for donated pharmaceuticals that you have been auditing for the last few years.
If you have a budget of 100 or 300 hours, it might be wise to allocate a few hours to read beyond AICPA risk alerts and Accord position papers. You can browse my blog for discussions, which contain links to other resources that also discuss the accounting and valuation issues.
It is my considered opinion that many of the valuations are not supportable under GAAP. The timing of SFAS 157 isn’t the issue.
The amount of scrutiny on your client’s valuation methodologies is high and increasing.
…
An open letter to the CPAs who audit R&D charities receiving GIK medsRead More »
An open letter to the CPAs who audit R&D charities receiving GIK meds Read More »